La Jolla Institute for Allergy and Immunology
Leinco Technologies Licenses SARS-CoV-2 Antibodies from La Jolla Institute for Immunology
Leinco will use the antibodies for diagnostic applications and will make the antibodies commercially available as part of their research tools catalog.